History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019
Publication
, Conference
Levintow, SN; Wiener, C; Orroth, KK; Gill, K; Mullard, A; Brookhart, MA; McGrath, LJ
Published in: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
2020
Duke Scholars
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
2020
Volume
29
Start / End Page
55 / 55
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Levintow, S. N., Wiener, C., Orroth, K. K., Gill, K., Mullard, A., Brookhart, M. A., & McGrath, L. J. (2020). History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 29, pp. 55–55).
Levintow, Sara N., Catie Wiener, Kate K. Orroth, Karminder Gill, Andrew Mullard, M Alan Brookhart, and Leah J. McGrath. “History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019.” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 29:55–55, 2020.
Levintow SN, Wiener C, Orroth KK, Gill K, Mullard A, Brookhart MA, et al. History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020. p. 55–55.
Levintow, Sara N., et al. “History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 29, 2020, pp. 55–55.
Levintow SN, Wiener C, Orroth KK, Gill K, Mullard A, Brookhart MA, McGrath LJ. History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020. p. 55–55.
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
2020
Volume
29
Start / End Page
55 / 55
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
- 1117 Public Health and Health Services
- 1115 Pharmacology and Pharmaceutical Sciences